The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.
“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.
The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.
“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.
“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”
Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.
“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”
11 November 2022
Commentator Russell Brown takes a look at the ACT's road to decriminalising drug possession, and asks what New Zealand could learn.
30 September 2022
Drug Foundation Communications Advisor Feilidh Dwyer visits a thought-provoking MDMA pop-up shop in Utrecht.
08 July 2022
Too many kiwis are still buying medicinal cannabis on the black market. We asked two leading experts for some harm reduction tips to keep th...
04 July 2022
Drug Foundation executive director Sarah Helm discusses recent fentanyl overdoses in Wairarapa and how we can avoid fentanyl deaths in futur...
Back to top